New Generation of Kits Delivers Faster Recovery of More DNA Results from a Wider Range of Samples

CARLSBAD, Calif — Applied Biosystems, part of Life Technologies Corporation (NASDAQ:LIFE), today announced a new generation of forensic DNA kits with chemistry reagents designed to address the increasing challenges facing 21st century forensic laboratories. The new AmpFℓSTR® Identifiler® Direct, Identifiler® Plus and NGM™ PCR Amplification Kits provide a new level of performance, efficiency and data quality, enabling faster recovery of more DNA results from a wider range of samples. These kits are the latest additions to the Applied Biosystems leading-edge portfolio of validated human identification workflow solutions, including genetic analyzers, reagent kits, PCR and Real-Time PCR systems and software applications.

Today’s forensic DNA laboratories are expected to provide efficient, high-quality results from samples that are increasing in quantity and complexity. Much of the increased demand is driven by the creation or expansion of forensic DNA databases worldwide. Recently, the National DNA Index System (NDIS) in the United States exceeded seven million offender DNA profiles and continues to expand rapidly.

Applied Biosystems is introducing the world’s first commercially-available kit designed to enable direct amplification of database samples to assist forensic laboratories address the challenge associated with analyzing a rapidly increasing quantity of samples. The Identifiler® Direct Kit eliminates the entire step of DNA extraction and purification for single source samples on standard FTA® cards, dramatically simplifying the processing workflow and automation requirements as well as accelerating testing by as much as 30 percent.

The submission of more complex casework samples from law enforcement agencies is also increasing substantially as DNA evidence is more routinely used in investigations of a wider range of criminal activity, including property crimes. As a result, many forensic laboratories now have to process more samples that contain low levels of DNA, have multiple contributors, are degraded and/or contain substances that inhibit PCR reactions.

To address this challenge, Applied Biosystems has developed the Identifiler® Plus Kit, which applies next-generation PCR amplification technology to provide enhanced sensitivity, improved performance on mixtures and the ability to overcome high levels of PCR inhibitors. This will help enable forensic analysts to recover more interpretable results from a wider range of DNA evidence samples.

In European Union countries, forensic DNA laboratories face these same challenges, but are also striving to implement routine cross-border data exchange. To meet this need, Applied Biosystems has developed the NGM™ Kit (or “Next Generation Multiplex”), which includes the five new genetic markers recommended by the European Network of Forensic Science Institutes (ENFSI) and the European DNA Profiling Group (EDNAP) to provide powerful discrimination and support European cross-border data sharing initiatives. This new kit also provides the highest level of data quality and robustness for improved recovery of results from challenging samples.

Lynne Burley, Supervising Criminalist at the Santa Clara County Crime Laboratory (CA), which served as one of the test sites for the Identifiler® Plus Kit

“Like many forensic DNA laboratories, we need to improve efficiency while enhancing our capability to detect results from the increasing quantity of more challenging samples. This is why we are seeking better solutions, and why we see great promise in the results we generated as a test site for Applied Biosystems’ next-generation PCR amplification kits.”

Leonard Klevan, Ph.D., President of Applied Markets at Life Technologies

“Life Technologies is once again setting a new standard in forensic DNA technologies with our next-generation Applied Biosystems-branded solutions. These provide forensic labs with improved tools to deliver more efficient, high quality DNA results, expanding the ability to use DNA identification to solve and prevent a wider variety of violent and non-violent crimes.”

Additional Resource

Forensic DNA product information

About Life Technologies (www.lifetechnologies.com)

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference, please visit our website: www.lifetechnologies.com.

Life Technologies’ Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

For Research Use Only. Not for use in diagnostic procedures.

Copyright 2009. Life Technologies Corporation. All rights reserved. Applied Biosystems is a registered trademark of Life Technologies or its subsidiaries in the United States and/or certain other countries.